We are live on ! Find out more
ACH

Accendra Health

0.4432 USD
-0.0297
6.28%
At close Updated Oct 8, 4:00 PM EDT
Pre-market
After hours
0.4618
+0.0186
4.2%
1 day
-6.28%
5 days
-20.86%
1 month
-59.71%
3 months
-86.02%
6 months
-82.75%
Year to date
-80.9%
1 year
-90.61%
5 years
-98.6%
10 years
-98.7%
 

About: Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.

Employees: 6,500

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 11.1%
Neutral 77.8%
Negative 11.1%
Negative
Zacks Investment Research
2 days ago
New Strong Sell Stocks for October 6th
VLVLY, ACH and CCJ have been added to the Zacks Rank #5 (Strong Sell) List on October 6th, 2026.
New Strong Sell Stocks for October 6th
Neutral
Business Wire
21 days ago
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smith, who has served on the Company's Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August. Gardner-Smith brings deep experience running large-scale patient care operations and guiding.
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth
Neutral
Business Wire
1 month ago
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce o.
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans
Neutral
Seeking Alpha
1 month ago
Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript
Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript
Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript
Neutral
Business Wire
1 month ago
Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) designed to protect long-term shareholder value by facilitating the Company's ability to preserve its net operating loss carryforwards (“NOLs”) and certain other tax attributes. A company generally experiences an ownership change if the percentage of the value of its stock owned by certain “5-percen.
Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value
Neutral
Business Wire
1 month ago
Accendra Health Reports Second Quarter 2026 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the second quarter ended June 30, 2026. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. “Throughout the second quarter, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payor exi.
Accendra Health Reports Second Quarter 2026 Financial Results
Neutral
Business Wire
1 month ago
Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, after more than seven years with the Company. Mr. Pesicka will also retire from the Company's Board of Directors before the end of the year. The Board of Directors maintains a long-standing, robust succession planning process established to address officer success.
Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search
Positive
Seeking Alpha
2 months ago
Accendra Health Q2 Preview: Low Expectations Create Opportunity
Accendra Health remains a speculative buy despite recent share declines and sector-driven volatility. ACH's limited exposure to capitated contracts and prudent exit from risky agreements mitigate margin risk seen in peers like AHCO. Balance sheet restructuring has reduced gross borrowings by at least $350 million, extending maturities and enabling future deleveraging.
Accendra Health Q2 Preview: Low Expectations Create Opportunity
Neutral
Business Wire
2 months ago
Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the second quarter of 2026 on Monday, August 10, 2026, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058.
Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call
Neutral
Zacks Investment Research
3 months ago
Is the Options Market Predicting a Spike in Accendra Health Stock?
Investors need to pay close attention to ACH stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Accendra Health Stock?
Price charts implemented using Lightweight Charts™